Lab
Innovative Genomics LLC
Innovative Genomics LLC was paid $2.17M by Medicaid between Apr 2020 and Apr 2024, across 38 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.
33Billing provider infoINNOVATIVE GENOMICS LLC
SAN ANTONIO, TX 78229
SAN ANTONIO, TX 78229
33aNPI1629531769assigned 04/06/2019
33bProvider typeClinical Medical Laboratory
28Total paid$2.17M
24GClaims112,328
24DCodes billed38
24AFirst – last monthApr 2020 – Apr 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#40 of 436
Median peer was paid$17K
This provider vs. median126×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,133 | $111K | |
| 2021 | 17,369 | $491K | |
| 2022 | 60,753 | $1.30M | |
| 2023 | 28,914 | $244K | |
| 2024incomplete | 3,159 | $28K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 53% | 23,343 | 14,691 | $1.14M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 13% | 19,447 | 12,217 | $291K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 13% | 13,753 | 5,972 | $282K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 12% | 16,468 | 4,093 | $267K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.9% | 3,620 | 2,683 | $41K |
| 87481 | 1.9% | 4,979 | 3,566 | $40K | |
| 87631 | <1% | 1,021 | 766 | $16K | |
| 87529 | <1% | 1,581 | 1,234 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,608 | 1,307 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,421 | 1,171 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,538 | 1,259 | $8K |
| 87641 | <1% | 4,072 | 3,205 | $8K |
26 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,784 | $7K |
| 87653 | <1% | 3,054 | $7K | |
| 87563 | <1% | 1,531 | $7K | |
| 87640 | <1% | 3,355 | $6K | |
| 87500 | <1% | 3,017 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 757 | $4K |
| 87511 | <1% | 791 | $3K | |
| 87581 | <1% | 1,138 | $3K | |
| 87551 | <1% | 241 | $1K | |
| 87541 | <1% | 207 | $709.14 | |
| 87556 | <1% | 173 | $707.90 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 489 | $274.12 |
| 81001 | <1% | 240 | $62.42 | |
| 87561 | <1% | 14 | $56.14 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 23 | $51.33 |
| 87625 | <1% | 33 | $40.05 | |
| 87634 | 0% | 82 | $0.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 82 | $0.00 |
| 81225 | 0% | 31 | $0.00 | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 198 | $0.00 |
| 87486 | 0% | 124 | $0.00 | |
| 81226 | 0% | 31 | $0.00 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 20 | $0.00 |
| 87498 | 0% | 20 | $0.00 | |
| 87496 | 0% | 20 | $0.00 | |
| 87532 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHOCRON, DIEGO (CFO)